Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer（NK）Cells

Inclusion Criteria: 1. Age from 18 to 75 years (including boundary values); 2. Diagnosed with histologically and cellularly confirmed cancer of lung, breast, pancreas, ovary, or colon; 3. At least 8 weeks since any prior systemic therapy to treat the underlying malignancy (standard or investigational); 4. Life expectancy \> 6 months, and performance status（KPS）\> 60 points; 5. Organ functions meet the following criteria: 1. Blood bilirubin \< 2mg/dL, 2. Aspartate transaminase（AST）\<100 IU/L, 3. Alanine transaminase（ALT） \<100 IU/L, 4. Creatinine \<1.5 mg/dL, 5. Urea nitrogen ≤ 25 mg/dL, 6. Hemoglobin ≥ 9.0 g/dL, 7. White blood cell count\>3.5×109/L, 8. Neutrophil count \>1.5x109/L, 9. Platelet count \> 80 × 109 /L, 10. Hematocrit \>0.20, 6. No severe infections. Exclusion Criteria: 1. Subjects who take combined systemic steroids within 2 weeks prior to treatment (except inhaled steroids); 2. Patients who take chemotherapy within 1 month prior to treatment; 3. Subjects receiving drugs that stimulate the production of bone marrow hematopoietic cells within two weeks prior to treatment; 4. Patients with T lymphoma and NK cell lymphoma; 5. Patients with autoimmune diseases, including but not limited to lupus erythematosus, rheumatoid arthritis, etc.; 6. Seriously uncontrollable infected patients; 7. Patients who are allergic to the biological agents in this treatment; 8. Patients with organ transplantation or organ failure; 9. Subjects with severe cardiovascular disease and severe renal failure; 10. Patients who are undergoing treatment of immunosuppressive drugs or long-term administration of immunosuppressive drugs after organ transplantation; 11. Patients with active infection or fever; 12. Subjects with severe cardiovascular and cerebrovascular diseases, diabetes and renal dysfunction; 13. Subjects with pregnancy or during the lactating period.